Study #2017-0495
A Phase 2, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
MD Anderson Study Status
Enrolling
Treatment Agent
Ruxolitinib, Navitoclax
Description
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Information and next steps
Disease:
Myelofibrosis (MF)
Study phase:
II
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.